2026-04-26T23:29:38Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/226282024-11-29T00:59:42Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author Barrios Tascon, Ana author Centeno Malfaz, Fernando author Rojo Sombrero, Henar author Fernandez-Cooke, Elisa author Sanchez-Manubens, Judith author Perez-Lescure Picarzo, Javier author Grupo de Cardiología Clínica SECPCC 2024-09-06T09:56:43Z 2024-09-06T09:56:43Z 2018-09 Barrios Tascon A, Centeno Malfaz F, Rojo Sombrero H, Fernandez-Cooke E, Sanchez-Manubens J, Perez-Lescure Picarzo J, et al. National consensus on the cardiological treatment and follow-up of Kawasaki disease. An Pediatr. 2018 Sep;89(3). Epub 2018 May 16. 1695-4033 http://hdl.handle.net/20.500.13003/17448 https://hdl.handle.net/20.500.12105/22628 29778491 10.1016/j.anpedi.2018.04.003 1696-4608 Anales de Pediatria 2-s2.0-85047198349 457112200011 L2000774972 Kawasaki disease is a self-limiting acute vasculitis that affects small and medium-sized vessels, and is the most common cause of acquired heart disease in children in our environment. Up to 25% of untreated patients develop coronary aneurysms. It is suspected that an infectious agent may be the trigger of the disease, but the causative agent is still unknown. Based on the previous evidence, recommendations are proposed for the diagnosis, treatment of acute disease, and the long-term management of these patients, in order to unify criteria. The diagnosis must be quick, based on easy-to-use algorithms and with the support of complementary tests. This document includes the indication of available imaging techniques, as well as the planning of cardiological examinations based on the initial involvement. Intravenous immunoglobulin is the basis of the initial treatment. The role of corticosteroids is still controversial, but there are studies that support its use as adjuvant treatment. A multidisciplinary working group has developed a scheme with different treatment guidelines depending on the risk factors at diagnosis, the patient's clinical situation, and response to previous treatment, including indications for thromboprophylaxis in patients with coronary involvement. The stratification of risk for long-term treatment is essential, as well as the recommendations on the procedures based on the initial cardiological involvement and its progression. Patients with coronary aneurysms require continuous and uninterrupted cardiological monitoring for life. spa Kawasaki disease Mucocutaneous lymphnode syndrome Vasculitis Arteritis Coronary aneurysm Coronary vessels Aneurysm Immunoglobulins intravenous Steroids Consensus National consensus on the cardiological treatment and follow-up of Kawasaki disease research article